ObjectiveTo investigate the clinical effect of atorvastatin combined with ticagrelor in the treatment of patients with angina pectoris of coronary heart disease. MethodsA total of 76 patients with angina pectoris of coronary heart disease were selected as the research objects, and they were randomly divided into observation group and control group, with 38 cases in each group. The patients in the control group were treated with atorvastatin, while the patients in the observation group were treated with ticagrelor based on the control group, and both groups were treated for 4 weeks. The clinical efficacy, serum myocardial enzyme indices and inflammatory factors levels before and after treatment, and the occurrence of adverse reactions during treatment were compared between the two groups. ResultsThe effective rate of the observation group was 94.74%, which was significantly higher than the 78.95% of the control group (P＜0.05). After 4 weeks of treatment, the levels of serum cardiac troponin I, creatine kinase, creatine kinase isoenzymes, interleukin-6, high-sensitivity C-reactive protein, and tumor necrosis factor-α in the observation group were lower than those in the control group (all P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (5.26% vs. 13.16%) (P＞0.05). ConclusionAtorvastatin combined with ticagrelor tablets has a significant clinical effect in the treatment of patients with angina pectoris of coronary heart disease, which can effectively improve their levels of myocardial enzyme indices and inflammatory factors, with high safety.

无